Drug Profile
HUEXC 030
Alternative Names: HUEXC-030Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Orient Pharma
- Class Hepatoprotectants; Small molecules
- Mechanism of Action Amidohydrolase inhibitors; Cytochrome P-450 CYP2E1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Liver disorders
Most Recent Events
- 15 Jun 2022 Orient Pharma completes a phase II/III trial in Liver disorders in Taiwan (NCT02467608)
- 03 May 2021 Suspended - Phase-II/III for Liver disorders in Taiwan (PO) (NCT02467608)
- 30 Dec 2019 No development reported - Phase-II/III for Liver disorders in Taiwan (PO)